Our results demonstrated that CD147 overexpression significantly promoted TAC-induced cardiac remodeling, while glycosylation site mutagenesis notably weakened the detrimental effects of CD147 via suppression of CD147-TRAF2 binding and downstream activation of TAK1 signalling. The gene discussed is TRAF2; the disease is persistent truncus arteriosus.